National Peroxide Ltd Downgraded to Hold Amid Mixed Financial and Technical Signals

Quality Assessment Deteriorates on Weak Long-Term Fundamentals

The most significant factor behind the downgrade is the decline in the company’s quality grade from average to below average. Over the past five years, National Peroxide has experienced a negative compound annual growth rate (CAGR) in sales of -6.72% and a steep decline in EBIT growth at -24.68%. These figures highlight a persistent erosion in core operating performance, signalling challenges in sustaining profitable growth.

Despite maintaining a low debt burden, with an average debt to EBITDA ratio of 0.85 and net debt to equity at zero, the company’s returns remain subdued. The average return on capital employed (ROCE) stands at a modest 2.08%, while return on equity (ROE) averages 2.63%, indicating limited profitability relative to shareholder funds. Institutional holding is negligible at 0.01%, and promoter shareholding remains dominant, which may raise concerns about liquidity and governance.

Compared to peers within the commodity chemicals industry, National Peroxide’s quality rating now lags behind companies such as Stallion India and Titan Biotech, which maintain average quality grades. This downgrade reflects a reassessment of the company’s ability to generate sustainable earnings growth and efficient capital utilisation over the medium to long term.

Valuation Remains Attractive Despite Mixed Returns

On the valuation front, National Peroxide presents a compelling case for investors seeking value in the micro-cap segment. The stock is currently trading at ₹569.00, up 2.33% on the day, but still below its 52-week high of ₹770.00. Its price-to-book (P/B) ratio is a modest 0.9, suggesting the market values the company below its net asset base, which could indicate undervaluation relative to peers.

Moreover, the company’s price-to-earnings growth (PEG) ratio is an attractive 0.1, reflecting the market’s cautious optimism given the recent surge in profits. National Peroxide reported a remarkable 333.33% growth in net profit in Q4 FY25-26, with net sales reaching a quarterly high of ₹85.68 crores and PBDIT at ₹14.88 crores. The operating profit margin also improved to 17.37%, the highest recorded in recent quarters.

However, the stock’s one-year return of -22.44% significantly underperformed the broader market benchmark, with the BSE500 index generating a marginal 0.15% return over the same period. This divergence suggests that while the company’s fundamentals have shown pockets of strength, market sentiment remains cautious, possibly due to the weak long-term growth trajectory.

Financial Trend Shows Mixed Signals with Strong Quarterly Performance

National Peroxide’s recent financial trend presents a complex picture. The company has delivered very positive quarterly results for Q4 FY25-26, with net sales and operating profits reaching record highs. The net profit growth of 333.33% in the quarter is particularly noteworthy, signalling a potential turnaround in operational efficiency and profitability.

However, these short-term gains contrast sharply with the weak five-year trend in operating profits, which have declined at a CAGR of -24.68%. This inconsistency raises questions about the sustainability of the recent performance spike. The company’s average tax ratio of 23.56% and zero pledged shares indicate a stable tax environment and no immediate promoter-related financial distress.

Despite the encouraging quarterly results, the average ROE of 2.63% and ROCE of 2.08% remain low, reflecting limited returns on invested capital. This weak fundamental strength over the long term has contributed to the downgrade in the overall investment rating.

Technical Indicators Shift to Mildly Bullish, Offering Short-Term Optimism

On the technical front, National Peroxide’s trend has improved from mildly bearish to mildly bullish, providing some optimism for short-term investors. Key weekly indicators such as the MACD and Bollinger Bands have turned bullish, while daily moving averages also support a positive momentum shift. The KST indicator on a weekly basis confirms this bullish tilt.

However, monthly technical signals remain mixed, with the RSI and Bollinger Bands still indicating bearish tendencies. Dow Theory assessments show a mildly bearish weekly outlook but a mildly bullish monthly perspective, underscoring the transitional nature of the stock’s technical position.

Price action has been relatively volatile, with the stock trading between ₹350.00 and ₹770.00 over the past 52 weeks. The recent price rise to ₹569.00, up from the previous close of ₹556.05, reflects renewed buying interest, but the stock’s one-month return of -11.48% contrasts with a 2.55% gain in the Sensex, highlighting ongoing market caution.

Conclusion: Hold Rating Reflects Balanced View of Risks and Opportunities

The downgrade of National Peroxide Ltd’s investment rating from Buy to Hold by MarketsMOJO on 17 June 2026 reflects a balanced assessment of the company’s current position. While the recent quarterly results and improved technical indicators offer encouraging signs of operational recovery and short-term momentum, the weak long-term financial trends and below-average quality grade temper expectations.

Valuation metrics remain attractive, with the stock trading at a discount to book value and a low PEG ratio, suggesting potential upside if the company can sustain its recent profit growth. However, the persistent underperformance relative to the broader market and low returns on equity highlight ongoing challenges.

Investors should monitor National Peroxide’s ability to convert its recent positive momentum into consistent long-term growth before considering an upgrade in rating. For now, the Hold rating signals caution, recommending a wait-and-watch approach amid mixed signals across quality, valuation, financial trends, and technicals.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →